Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

1,086 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Needed: Antimicrobial Development.
Cox E, Nambiar S, Baden L. Cox E, et al. N Engl J Med. 2019 Feb 21;380(8):783-785. doi: 10.1056/NEJMe1901525. N Engl J Med. 2019. PMID: 30786194 No abstract available.
Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis.
Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, Pulcini C, Kahlmeter G, Kluytmans J, Carmeli Y, Ouellette M, Outterson K, Patel J, Cavaleri M, Cox EM, Houchens CR, Grayson ML, Hansen P, Singh N, Theuretzbacher U, Magrini N; WHO Pathogens Priority List Working Group. Tacconelli E, et al. Among authors: cox em. Lancet Infect Dis. 2018 Mar;18(3):318-327. doi: 10.1016/S1473-3099(17)30753-3. Epub 2017 Dec 21. Lancet Infect Dis. 2018. PMID: 29276051
Editorial Commentary: A Collaborative Model for Endpoint Development: Advancing the Science of Antibacterial Drug Clinical Trials.
Toerner JG, Cox E. Toerner JG, et al. Among authors: cox e. Clin Infect Dis. 2016 Mar 1;62(5):608-9. doi: 10.1093/cid/civ1007. Epub 2015 Dec 13. Clin Infect Dis. 2016. PMID: 26668336 Free PMC article. No abstract available.
Combating Emerging Threats--Accelerating the Availability of Medical Therapies.
Borio L, Cox E, Lurie N. Borio L, et al. Among authors: cox e. N Engl J Med. 2015 Sep 10;373(11):993-5. doi: 10.1056/NEJMp1508708. Epub 2015 Aug 5. N Engl J Med. 2015. PMID: 26244879 No abstract available.
Facilitating Antibacterial Drug Development in a Time of Great Need.
Cox E, Cavaleri M, Eichler HG, Woodcock J, Borio L. Cox E, et al. Clin Infect Dis. 2016 Aug 15;63 Suppl 2:S27-8. doi: 10.1093/cid/ciw257. Clin Infect Dis. 2016. PMID: 27481949
The Fight Against Multidrug-Resistant Bacteria.
Boucher HW, Cosgrove SE, Cox E, Talbot GH. Boucher HW, et al. Among authors: cox e. Ann Intern Med. 2017 Jan 3;166(1):78-79. doi: 10.7326/L16-0584. Ann Intern Med. 2017. PMID: 28030674 No abstract available.
Evaluating Ebola therapies--the case for RCTs.
Cox E, Borio L, Temple R. Cox E, et al. N Engl J Med. 2014 Dec 18;371(25):2350-1. doi: 10.1056/NEJMp1414145. Epub 2014 Dec 3. N Engl J Med. 2014. PMID: 25470568 No abstract available.
The Emergency Use Authorization of peramivir for treatment of 2009 H1N1 influenza.
Birnkrant D, Cox E. Birnkrant D, et al. Among authors: cox e. N Engl J Med. 2009 Dec 3;361(23):2204-7. doi: 10.1056/NEJMp0910479. Epub 2009 Nov 2. N Engl J Med. 2009. PMID: 19884645 No abstract available.
FDA approval of bedaquiline--the benefit-risk balance for drug-resistant tuberculosis.
Cox E, Laessig K. Cox E, et al. N Engl J Med. 2014 Aug 21;371(8):689-91. doi: 10.1056/NEJMp1314385. N Engl J Med. 2014. PMID: 25140952 No abstract available.
A US Food and Drug Administration perspective on evaluating medical products for Ebola.
Russek-Cohen E, Rubin D, Price D, Sun W, Cox E, Borio L. Russek-Cohen E, et al. Among authors: cox e. Clin Trials. 2016 Feb;13(1):105-9. doi: 10.1177/1740774515620613. Epub 2016 Jan 14. Clin Trials. 2016. PMID: 26768565 No abstract available.
1,086 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback